Defining Adequate Surgery for Primary Melanoma

New England Journal of Medicine

Volumn 350, Issue 8, 2004, Pages 823-825

  Krown, Susan E ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; METHODOLOGY; MORTALITY; OUTCOMES RESEARCH; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; SURGERY; SURGICAL TECHNIQUE; SURVIVAL RATE; THICKNESS;

HUMANS; LYMPHATIC DISEASES; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURGICAL PROCEDURES, OPERATIVE; SURVIVAL RATE;

EID: 1142310621     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe038235     Document Type: Editorial

References (12)

1. Cancer facts & figures 2003. Atlanta: American Cancer Society, 2003. (Accessed January 29, 2004, at http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf)
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
3. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 2002;137:1101-5.
4. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101-8.
5. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757-66.
6. Cochran AJ, Wen R, Wang HJ, Elashoff R, Morton DL. Prediction of metastatic melanoma in non-sentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (in press).
7. Busam KJ. Advances in molecular staging of melanoma patients: multimarker analysis of archival lymph node tissue. J Clin Oncol 2003;21:3550-1.
8. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003;21:3566-72.
9. Shivers SC, Li W, Lin J, et al. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 2001;158:187-99.
10. Rimoldi D, Lemoine R, Kurt AM, et al. Detection of micrometastases in sentinel lymph nodes from melanoma pafients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 2003;13:511-20.
11. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17:3238-44.
12. Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2001;2:205-11.